Beone MedicinesONC.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Beone Medicines (ONC.O) trades at a P/E of 64.00x, P/B of 8.10x, P/S of 6.85x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 40th percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/B sits at the 73rd percentile over the trailing 10Y window (vs. 74th percentile over 3Y); P/S sits at the 20th percentile over the trailing 10Y window (vs. 61st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 86th percentile within its industry and the 88th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 33.4 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Beone Medicines operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ONC · ONC
Want the full picture on whether Beone Medicines (ONC.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 64.00 | ||||||
| P/B (MRQ) | 8.10 | ||||||
| P/S (TTM) | 6.85 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |